Barasertib (AZD1152-HQPA)

製品コード:S1147 別名:AZD2811, INH-34, Barasertib-HQPA , Defosbarasertib

For research use only.

Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

Barasertib (AZD1152-HQPA)化学構造

CAS No. 722544-51-6

サイズ 価格(税別)
10mM (1mL in DMSO) JPY 29800
JPY 21900
JPY 36800
JPY 57700
JPY 113200

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(105)

製品安全説明書

Aurora Kinase阻害剤の選択性比較

相関Aurora Kinase製品

生物活性

製品説明 Defosbarasertib (AZD1152-HQPA, AZD2811, INH-34, Barasertib-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
ターゲット
Aurora B [1]
(Cell-free assay)
0.37 nM
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHzNE02ODBibl2= MUS0POKhcA>? M4XB[GlEPTB;MkWgcm0> NYXYZ|lpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c3PTlpPkK1Nlc4PjV7PD;hQi=>
LNCaP M2HnV2Fxd3C2b4Ppd{BCe3OjeR?= NX\L[HE5OC13MECgcm0> MY[0POKhcA>? NH3aV4FqdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRpKHSqcn;1[4gh[2G|cHHz[U0{KHWycnXneYxifGmxbh?= MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e2OVkoRjJ3Mke3OlU6RC:jPh?=
LNCaP NUDCZow3TnWwY4Tpc44hSXO|YYm= NFq5T4k2OCCwTR?= MljkOFghcA>? NWfuflN2cW6mdXPld{BucWO{b371Z4xmcSC5aYToJIFv\XWpZX7pZ{Bu\WOqYX7pd40> MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e2OVkoRjJ3Mke3OlU6RC:jPh?=
Ramos MVnGeY5kfGmxbjDBd5NigQ>? M2XIV|UxOCCwTR?= MU[wMVczKGh? NWroNFEycW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl Mm\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Daudi  MlrxSpVv[3Srb36gRZN{[Xl? MVe1NFAhdk1? NWXafIV7OC15MjDo NHPJRoFqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= MlnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L540 MkHoSpVv[3Srb36gRZN{[Xl? MXq1NFAhdk1? MVewMVczKGh? NITGRpFqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= M4\1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
BJAJ NHjrS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK1NFAhdk1? M{L6TFAuPzJiaB?= MU\pcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M{TZeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
Ramos NGnIV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTFOVAxKG6P MX2wMVczKGh? MX\pcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji M2XLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXhXpE2ODBibl2= MmH4NE04OiCq NVG3dJhjcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Daudi  MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXSOVAxKG6P NHu5Z5cxNTd{IHi= MmXMbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NW\MblRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
L428 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULRepdSPTByIH7N M{K0WFAuPzJiaB?= MYHpcohq[mm2czDj[YxtKGe{b4f0bC=> MnmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
KM-H2 NEHvW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLJUXBmPTByIH7N MVOwMVczKGh? M{O0NolvcGmkaYTzJINmdGxiZ4Lve5Rp MonmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
HDLM-2 Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUK1NFAhdk1? MlrUNE04OiCq M4W0RYlvcGmkaYTzJINmdGxiZ4Lve5Rp MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L450 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi4[2I2ODBibl2= MlvJNE04OiCq MYXpcohq[mm2czDj[YxtKGe{b4f0bC=> M2G1TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{exOFQ3Lz5{MUO3NVQ1PjxxYU6=
BJAJ NUXRboU4SXCxcITvd4l{KEG|c3H5 MVG1NFAhdk1? M{L4NVAuPzJiaB?= MmnhbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NFrTSXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Ramos MXvBdI9xfG:|aYOgRZN{[Xl? NHjTTFI2ODBibl2= NYD4O3ZlOC15MjDo NUn3dGZvcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Raji M1zZVWFxd3C2b4Ppd{BCe3OjeR?= MV61NFAhdk1? NXjSV21COC15MjDo MXXpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NGj6fFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  MnTRRZBweHSxc3nzJGF{e2G7 Mn[yOVAxKG6P M4nnclAuPzJiaB?= MnrVbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MlyyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L428 NYOy[ZlxSXCxcITvd4l{KEG|c3H5 M{Hv[FUxOCCwTR?= NF\ScGUxNTd{IHi= NVLSNVZmcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NUnPcnF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
KM-H2 M{O2XmFxd3C2b4Ppd{BCe3OjeR?= MVK1NFAhdk1? MnPzNE04OiCq MWPpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NIi2U|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
HDLM-2 NUjLbFdKSXCxcITvd4l{KEG|c3H5 MlTjOVAxKG6P MWCwMVczKGh? NXjFfmk2cW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NVHIT3FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
L450 M{f0VmFxd3C2b4Ppd{BCe3OjeR?= NFryXZI2ODBibl2= MmHVNE04OiCq M37kNYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NXTwXI5ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
SW620 NIPVVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorXSWM2OD1zMNMxNk4yKG6P NVvuSWw5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOFUxQTBpPkKxNlQ2ODlyPD;hQi=>
HCT116 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjFR|UxRTFzwsGzMlMhdk1? NVjne5JYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOFUxQTBpPkKxNlQ2ODlyPD;hQi=>
MDA-MB-435 M36ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PwVVAuOTByMECgcm0> M13qelIuPSCm NXnkbJBGTE2VTx?= NFPqdGtKSzVyPUGyOUBvVQ>? NG\Z[ZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-468 NVzP[mN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqwMVExODByIH7N NX;5VoxGOi13IHS= Mnz2SG1UVw>? MVHJR|UxRTF2IH7N NHe2O|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
MDA-MB-231 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;EWVAuOTByMECgcm0> NUD5U5d4Oi13IHS= NFztN5VFVVOR MYHJR|UxRTFyNTDuUS=> M4fxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
BT474 NXrie4NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW4NE0yODByMDDuUS=> MnHnNk02KGR? M2fB[GROW09? NX[zTZFZUUN3ME24JI5O NVPWc5NRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
MDA-MB-361 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjNe5AxNTFyMECwJI5O NYThNG5DOi13IHS= NGHKW2JFVVOR NEW2VHJKSzVyPUewJI5O M1eyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
HER18 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHyNFA4OC1zMECwNEBvVQ>? MoLTNk02KGR? M1vRdGROW09? NID5U4JKSzVyPUKwJI5O MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
HER18 M4rnd2Fxd3C2b4Ppd{BCe3OjeR?= M{POV|ExOCCwTR?= NYPm[HREOC9{ND:0PEBp MX;EUXNQ M1G4T4lv\HWlZYOgZZBweHSxc3nzJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNicH;0[Y51cWGu MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-231 MXjBdI9xfG:|aYOgRZN{[Xl? NXu1To5wOTB3IH7N M4HqVFAwOjRxNEigbC=> MXHEUXNQ M4\w[Ylv\HWlZYOgZZBweHSxc3nzJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNicH;0[Y51cWGu NFnkcGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG3OVkzPid-MkCxO|U6OjZ:L3G+
JHH-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlNE4{6oDVMUCwNOKhdk1? NIXTSWI4OiCq M2C2XWVEPTB;MUeuOOKyOS5yIH7N NFLScXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
JHH-2 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW0fnUxOC5|4pETNVAxOMLibl2= NIXFUY04OiCq NX2xW3JFTUN3ME2yNVgvOMLzMUCuPEBvVQ>? NWPUOpJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
JHH-4 M2LPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMlPjiJNzMECwxsBvVQ>? NWX6RlFZPzJiaB?= NEfQS5JGSzVyPUG1OU43yrFzNj64JI5O NX;QWm5sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HuH-1 NXyyc2J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV74W|VnOC5|4pETNVAxOMLibl2= MmrDO|IhcA>? NILpfFhGSzVyPUK3MlPDuTVwMDDuUS=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
HuH-6 M2rNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkizNE4{6oDVMUCwNOKhdk1? Ml71O|IhcA>? NUO0W2JITUN3ME2zMlfDuTBwNjDuUS=> MmfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HuH-7 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzJNE4{6oDVMUCwNOKhdk1? MmPqO|IhcA>? MUHFR|UxRTZwONMxNE4{KG6P NVjTT|NZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HLE MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH2OHdROC5|4pETNVAxOMLibl2= M3Hq[lczKGh? NG\1dmRGSzVyPUS1MlnDuTZwNDDuUS=> NVO1TWpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HLF Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[0NE4{6oDVMUCwNOKhdk1? MnPlO|IhcA>? NF\4SppGSzVyPUGyOk4yyrFzMj6yJI5O M1X0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
PLC/PRF/5 M2PQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLPNE4{6oDVMUCwNOKhdk1? MluyO|IhcA>? NIrHO5VGSzVyPUe2MlnDuTlwOTDuUS=> M17IV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
SK-Hep1 M1fF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO1XnkxNjQkgKOxNFAxyqCwTR?= NW\6elZ[PzJiaB?= MVLFR|UxRTJzLkpCtVEvOiCwTR?= M{\6ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
Hep3B NEPOXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XieVAvO+LCk{GwNFDDqG6P MlznO|IhcA>? NWLiNJJxTUN3ME23MlbDuTFwMjDuUS=> M2LJOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HepG2 NVzl[FV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\sNE4{6oDVMUCwNOKhdk1? NIGwV3I4OiCq NVe2S4FCTUN3ME2xOE44yrFzLkegcm0> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
Ramos M4LUfGFxd3C2b4Ppd{BCe3OjeR?= MYqyOU82OC9zMECgcm0> M1fTVVQ5KGh? NGm1c4VqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> NV\HNpJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NlMyPjhpPkG5PFI{OTZ6PD;hQi=>
Daudi  M1zNSWFxd3C2b4Ppd{BCe3OjeR?= MWCyOU82OC9zMECgcm0> MXG0PEBp Mnr1bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz M3zrW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
BALM-14 MVXBdI9xfG:|aYOgRZN{[Xl? MYGxNk42NzJ3L{WwJI5O MXO0PEBp M2XObolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> M{\VUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
BALM-27 NHn1UIZCeG:ydH;zbZMhSXO|YYm= NFXmOGUyOi53L{K1M|UxKG6P MU[0PEBp M3X4Tolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> M4W1TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
NB4 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2weoNqOC5yMT:wMlEwOSEQvF2= MknCOFghcA>? M4faSolvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M13sdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{[3OFg1Lz5zOEO2O|Q5PDxxYU6=
HeLa NULGfVRuTnWwY4Tpc44hSXO|YYm= NICwV2IyKHWP MnnENlQhcHK| NHnwdIRKdmirYnn0bY9vKG:oIHH1do9z[SCEIHH1eI9xcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1OFkoRjJyNki0OVQ6RC:jPh?=
アッセイ
Methods Test Index PMID
Western blot AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN ; p53 / p21 / p-p38 / p38 26497213 24782314
Immunofluorescence p21 24782314
Growth inhibition assay Cell viability 26497213

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外

体内

左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。

7mg/mL

化学情報

分子量 507.56
化学式

C26H30FN7O3

CAS No. 722544-51-6
Storage 3年 -20°C
2年 -80°C in solvent
Smiles CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02579226 Completed Drug: AZD2811 Advanced Solid Tumours AstraZeneca October 28 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

回答
S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Tags: Barasertib (AZD1152-HQPA)を買う | Barasertib (AZD1152-HQPA) ic50 | Barasertib (AZD1152-HQPA)供給者 | Barasertib (AZD1152-HQPA)を購入する | Barasertib (AZD1152-HQPA)費用 | Barasertib (AZD1152-HQPA)生産者 | オーダーBarasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)化学構造 | Barasertib (AZD1152-HQPA)分子量 | Barasertib (AZD1152-HQPA)代理店